
|Articles|January 6, 2003
As pain management evolves, R.Ph.s can play a greater role
The pain management pharmaceuticals market in the U.S. is being driven by the continued development of selective cyclooxygenase-2 (COX-2) inhibitors, triptans, and extended-release formulations of opioid drugs, according to new analysis by the consulting firm of Frost & Sullivan. In 1997, the company released a similar report. In the intervening six years, the market has undergone dramatic changes.
Advertisement
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Oral Semaglutide Show Promise as New Benchmark for Diabetes Care, Cardiovascular Protection
2
Opioid Overdose Deaths Fall by 34% in 2025 | ASHP Midyear 2025
3
Limited Clinical Data Impact Cannabis Integration Into Standard Care | ASHP Midyear 2025
4
What TrumpRx Means for Independent Pharmacies and Their Patients
5




























































































































